Enjoy complimentary customisation on priority with our Enterprise License!
The bronchiectasis drugs market size is estimated to increase by USD 394.1 million, at a CAGR of 10.87% between 2023 and 2028. The market's expansion is influenced by several factors, including the increasing prevalence of risk factors associated with the condition, the availability of low-cost off-label generics, and the growing population of elderly individuals. However, challenges persist due to the lack of approved medications for the disease, underdiagnosis rates, and the preference for alternative treatment options. Despite the prevalence of risk factors driving demand, the absence of approved drugs remains a hurdle, along with issues related to underdiagnosis. Additionally, the availability of low-cost generics offers some relief, but alternative treatments still attract attention. As the geriatric demographic continues to grow, there's a pressing need for effective medications and improved diagnosis methods to address the rising demand and challenges associated with this market.
To learn more about this report, View Report Sample
The market share growth by the antibiotics segment will be significant during the forecast period. This segment consists of a wide range of off-label drugs, such as azithromycin, erythromycin, doxycycline, amoxicillin, ciprofloxacin, and macrolides, which are used for the treatment. Due to the absence of approved drug therapy for bronchiectasis, these antibiotics are very common in use.
Get a glance at the market contribution of various segments View the PDF Sample
The antibiotics segment ?was valued at ?USD 241.90 million?in 2018. The treatment with antibiotics is broadly classified as exacerbation treatment, chronic suppressive treatment, and eradication treatment. Antibiotic resistance in patients poses a challenge to the growth of the segment. A single antibiotic may not be able to inhibit all pathogens present and near the respiratory tract, even if every pathogen associated with the respiratory system is resistant to various antibiotics. Therefore, in order to attain the aim of a clinically meaningful result, different antibiotics must be used with each other. Hence, such factors are fuelling the growth of this segment during the forecast period.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 47% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. In this region, the increasing sales of various off-label drug therapies approved for other chronic respiratory conditions and the increasing prevalence of chronic respiratory diseases have fueled the growth of the market. The Market is experiencing significant growth due to various factors, including the increasing prevalence of bronchiectasis, advancements in drug development, and rising awareness of this respiratory condition. The healthcare systems of different countries are recognizing the importance of addressing unmet medical needs in the treatment of bronchiectasis, particularly idiopathic bronchiectasis. Hence, such factors are driving the market in North America during the forecast period.
In addressing conditions like chronic lung disease and respiratory problems, the market relies on advancements in technology for illness diagnostics and targeted therapies. Awareness initiatives by organizations like the American Thoracic Society promote understanding among smokers and drinkers. While generic medications, and otolaryngologists offer affordable options, telemedicine bridges gaps in access. However, challenges persist, including high healthcare costs and trade regulations, underscoring the importance of continued innovation in treating bronchiectasis. Bronchiectasis, often associated with respiratory problems and chronic lung disease, necessitates effective treatments. Medical advancements, including targeted therapies and telemedicine, offer hope. Awareness initiatives by organizations like the American Thoracic Society raise awareness. Despite high healthcare costs, access to generic medications and technology for illness diagnostics is vital. However, challenges such as trade regulations persist. The market for bronchiectasis drugs caters to the needs of smokers and drinkers seeking relief and improved quality of life.
The driving force behind the growth of the market lies in the escalating cases of associated risks, which are contributing to the increasing prevalence of bronchiectasis globally. This condition often arises from underlying health issues such as humoral immunodeficiency, inflammatory bowel diseases, rheumatologic diseases, COPD, and cystic fibrosis, all of which are of significant concern worldwide.
Additionally, external factors such as occupational exposure to poisonous gases, rising air pollution levels, and increasing smoking habits are further fueling the incidence of bronchiectasis. As the number of diagnosed cases continues to rise, the demand for effective treatment options becomes imperative, driving the market's growth trajectory. Consequently, the multitude of etiological factors underlying bronchiectasis is expected to positively impact the global market in the forecast period.
The growing awareness about bronchiectasis is the primary trend in the market. Bronchiectasis is often misunderstood as a common cough and cold, as the symptoms of most respiratory tract infections are overlapped. This results in underdiagnosing the infection, which reduces the use of treatment options and thus affects the growth of the market. In order to increase the prevalence of this disease, primary and secondary healthcare centers need to be better informed about it.
Many awareness programs have been put in place by a number of public and private organizations across the world to inform people about this. In addition, some companies are regularly organizing educational programs to inform healthcare professionals and patients of available therapeutic options for the treatment of bronchiectasis. Such awareness programs about the medications available for the treatment of bronchiectasis are expected to positively impact the market during the forecast period.
The lack of approved drugs for bronchiectasis is the major challenge to the growth of the global bronchiectasis drug market. The treatment options for bronchiectasis consist of medications, CPT, the use of lung airway devices, oxygen therapy, and surgery. The reason for the infection in bronchiectasis can be different, but a wide range of treatments is required in some cases. There are no authorized products in the global bronchiectasis drug market at present. However, drugs are used as OTC and off-label drug therapies largely to relieve the symptoms of other conditions, thus increasing the risk of bronchiectasis. However, human use of antibiotics category leads to a process of drug resistance.
Moreover, patient adherence to treatment continues to decline as a result of resistance to antibiotics. The growth of the market is projected to be limited due to the lack of availability of approved medicinal products, along with a weak therapeutic effect of Symptomative Medicines. In addition, there are only a few drugs available for the treatment of bronchiectasis. Also, R&D is focused more on the development of substitute therapies. Thus, the lack of approved drug therapies is expected to hinder the growth of the market in focus during the forecast period
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market forecast report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Market Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product launches, to enhance their presence in the market.
AbbVie Inc.: The company offers breast cancer therapeutics such as Veliparib, a PARP inhibitor.
The research report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Million" for the period 2023 to 2028, as well as historical data from 2018 to 2022 for the following segments.
You may also interested in below market reports:
The market addresses the treatment of bacterial lung infections, which can be caused by various factors such as bacterial load and disease phase. Pulmonologists utilize tools like High-Resolution Computed Tomography (HRCT) for accurate diagnosis and monitoring. The market landscape depends on the Bacterial lung infection, Cause of infection, API, Bronchiectasis incidence, Bronchial tubes, Inflammation, Mucolytics, Inhaled corticosteroids, Bronchodilators, Exacerbations, Lung function, New drugs, Collaborations, Healthcare providers, Lung health organizations, World Bronchiectasis Day, Unmet medical needs, Idiopathic bronchiectasis. Treatment options include generic drugs and branded drugs, each containing Active Pharmaceutical Ingredients (APIs) targeted at reducing bacterial load and improving therapeutic adoption rates.
In underdeveloped regions, the prevalence of bronchiectasis and the demand for low-priced drugs underscore the need for accessible treatment options. Incidence rates influence patient population demographics, driving research into new and innovative drugs tailored for personalized treatment approaches. Development activities focus on regulatory approvals and securing reimbursements within healthcare systems, facilitating access to advanced therapies. Advancements in drug formulations and improved diagnostics cater to rising awareness among aging populations about bronchiectasis management. The market's growth is propelled by continuous advancements in medical science and the pharmaceutical industry's commitment to enhancing patient outcomes in managing bacterial lung infections associated with bronchiectasis.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
174 |
|
Base year |
2023 |
|
Historic period |
2018 - 2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 10.87% |
|
Market growth 2024-2028 |
USD 394.1 million |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
9.52 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 47% |
|
Key countries |
US, Germany, UK, Canada, and China |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
AbbVie Inc., Akorn Operating Co. LLC, Amneal Pharmaceuticals Inc., Aurobindo Pharma Ltd., Bayer AG, Boehringer Ingelheim International GmbH, Dr Reddys Laboratories Ltd., Endo International Plc, GlaxoSmithKline Plc, Hikma Pharmaceuticals Plc, Lupin Ltd., Neopharma Corp., Pfizer Inc., Reckitt Benckiser Group Plc, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., Virtus Pharmaceuticals LLC, Wockhardt Ltd., and Zydus Lifesciences Ltd. |
|
Market dynamics |
Parent market analysis, Market forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, Market growth and Forecasting, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Market Segmentation by Distribution Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
